GLP-1 receptor agonists have become increasingly central to type 2 diabetes management, with tirzepatide, an agent with dual incretin activity (gastric inhibitory polypeptide (GIP)/GLP-1 agonism), showing superior weight loss and glycemic control compared to other GLP-1 analogs [4]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.